Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.72 |
| ▸ | FGFR2 | P21802 | 12/20 | 0.72 |
| ▸ | FGFR4 | P22455 | 12/20 | 0.72 |
| ▸ | FGFR3 | P22607 | 12/20 | 0.72 |
| ▸ | KDR | P35968 | 10/20 | 0.72 |
| ▸ | FLT1 | P17948 | 9/20 | 0.72 |
| ▸ | FLT4 | P35916 | 9/20 | 0.72 |
| ▸ | SRC | P12931 | 3/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | CSK | P41240 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249693 | 0.86 | FGFR1 (0.70) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2470675 | 0.85 | FGFR1 (0.85) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL31648262 | 0.84 | FGFR1 (0.76) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL30737861 | 0.83 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL5619204 | 0.82 | FGFR1 (0.84) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL31648009 | 0.82 | FGFR1 (0.78) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL3479994 | 0.82 | FGFR1 (0.87) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL22144559 | 0.82 | FGFR1 (0.95) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL19848922 | 0.82 | FGFR1 (0.80) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL22532273 | 0.81 | FGFR1 (0.82) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| US-8772269-B2 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| EP-2364699-A1 | Joint use of sulfonamide based compound with angiogenesis inhibitor | Eisai R&D Management Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | FGFR1 30/4885FGFR2 62/4885FGFR4 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.